We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

Back to rankings

0 hedge funds and large institutions have $0 invested in Portola Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 162 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 162 → 0 (-162)

100% less funds holding in top 10

Funds holding in top 10: 12 → 0 (-12)

100% less capital invested

Capital invested by funds: $1.34B → $0 (-$1.34B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 162

Holders
–
Holders Change
-162
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-12
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
162
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$126M
2
BlackRock
BlackRock
New York
-$115M
3
MF
Magnetar Financial
Illinois
-$72.3M
4
Goldman Sachs
Goldman Sachs
New York
-$64.6M
5
State Street
State Street
Massachusetts
-$63.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
51
Candriam SCA
Luxembourg
– -$6.09M -256,198 Closed
WAM
52
Wolverine Asset Management
Illinois
– -$4.57M -254,194 Closed
GI
53
GAMCO Investors
Connecticut
– -$4.33M -240,982 Closed
Renaissance Technologies
54
Renaissance Technologies
New York
– -$4.08M -226,500 Closed
GH
55
GAM Holding
Switzerland
– -$3.7M -205,800 Closed
UOC
56
UBS O'Connor
Illinois
– -$3.67M -204,017 Closed
PAMP
57
Polar Asset Management Partners
Ontario, Canada
– -$3.26M -181,200 Closed
CCM
58
Chicago Capital Management
Illinois
– -$3.17M -176,000 Closed
Ameriprise
59
Ameriprise
Minnesota
– -$3.03M -168,646 Closed
Capstone Investment Advisors
60
Capstone Investment Advisors
New York
– -$2.99M -166,055 Closed
Swiss National Bank
61
Swiss National Bank
Switzerland
– -$2.97M -164,957 Closed
FAM
62
Fred Alger Management
New York
– -$2.96M -164,710 Closed
Macquarie Group
63
Macquarie Group
Australia
– -$2.94M -163,578 Closed
California Public Employees Retirement System
64
California Public Employees Retirement System
California
– -$2.86M -158,900 Closed
NAM
65
Nexpoint Asset Management
Texas
– -$2.39M -132,607 Closed
WBC
66
Westpac Banking Corp
Australia
– -$2.32M -129,235 Closed
GC
67
Grace Capital
Massachusetts
– -$2.3M -127,729 Closed
State of Wisconsin Investment Board
68
State of Wisconsin Investment Board
Wisconsin
– -$2.23M -124,200 Closed
RhumbLine Advisers
69
RhumbLine Advisers
Massachusetts
– -$2.23M -124,022 Closed
GC
70
Guggenheim Capital
Illinois
– -$2.15M -119,705 Closed
California State Teachers Retirement System (CalSTRS)
71
California State Teachers Retirement System (CalSTRS)
California
– -$2.13M -118,398 Closed
TCM
72
Tekla Capital Management
Massachusetts
– -$1.97M -109,246 Closed
MSL
73
Mackay Shields LLC
New York
– -$1.88M -104,390 Closed
LBA
74
Letko, Brosseau & Associates
Quebec, Canada
– -$1.48M -82,000 Closed
UBS AM
75
UBS AM
Illinois
– -$1.42M -78,954 Closed
1 2
3
4 5

PTLA Hedge Fund Activity: Q3 2020 in Review

0 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q3 2020, worth a combined $0 — down 100% from $1.34B a quarter earlier.

Sellers outnumbered buyers: 162 funds closed out of PTLA and 0 opened new positions — a net loss of 162 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $126M sold.

  • 0 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q3 2020, down from 162 in Q2 2020.
  • Funds reported $0 of Portola Pharmaceuticals, Inc. stock for Q3 2020, down 100% quarter-over-quarter.
  • 0 funds opened new Portola Pharmaceuticals, Inc. positions in Q3 2020 and 162 closed out, a net change of -162 holders.
  • The largest Portola Pharmaceuticals, Inc. seller in Q3 2020 was Vanguard Group, an estimated $126M sold.

Based on aggregated 13F filings for Q3 2020.